ArticleNPJ precision oncology2025

Targeting high-risk MYC-overexpressed osteosarcoma with an Aurora kinase inhibitor:--results from a pilot umbrella trial.

Kai Tian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.